Lycia is using its proprietary lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases. Through the collaboration, Lycia will leverage Nona's proprietary Harbour Mice^® HCAb fully human antibody transgenic mice platform to discover novel antibodies for its LYTAC protein degrader therapeutics.

"We are pleased to enter into this collaboration with Lycia Therapeutics, extending our service footprint to the area of extracellular protein degradation.   We believe Lycia's leveraging of our antibody discovery capabilities will help accelerate its efforts to advance novel protein degrader therapeutics," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences said.

"Our LYTACs can uniquely address extracellular disease-driving targets that remain challenging for existing antibody and small molecule modalities. We look forward to deploying Nona Biosciences' technology to advance the discovery of novel therapeutics for currently underserved patient populations," said Steve Staben, Ph.D., Chief Scientific Officer of Lycia Therapeutics.